The Society of Gynecologic Oncology (SGO) annual meeting, held virtually again this year, had investigators report some very interesting new research developments. A partial list of pivotal data being presented is included below, but listen in to the highlights from the ASCO Post embedded below.
Another important finding is summarized in the following video:
Pivotal Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Chemotherapy in Patients with Advanced Endometrial Cancer to be Presented During Plenary SessionAdditional Plenary Session to Include Investigational Data on Farletuzumab Combination with Carboplatin in Patients with Low CA125 Platinum-Sensitive Ovarian Cancer